Recent Advances in Cancer Imaging with CuCl PET/CT

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2022 Apr 25

PMID 35464672

Authors

Fangyu Peng

Affiliations

Soon will be listed here.

Abstract

is required for cancer cell proliferation and tumor angiogenesis. Radioactive copper-64 chloride (CuCl) is a useful radiotracer for cancer imaging with position emission tomography (PET) based on increased cellular uptake of copper mediated by human copper transporter 1 (hCtr1) expressed on cancer cell membrane. Significant progress has been made in research of using CuCl as a radiotracer for cancer imaging with PET. Radiation dosimetry study in humans demonstrated radiation safety of CuCl. Recently, CuCl was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans. Based on the findings from the preclinical research studies, CuCl PET/CT also holds potential for diagnostic imaging of human hepatocellular carcinoma (HCC), malignant melanoma, and detection of intracranial metastasis of copper-avid tumors based on low physiological background of radioactive copper uptake in the brain. Copper-64 radionuclide emits both β and β particles, suggesting therapeutic potential of CuCl for radionuclide cancer therapy of copper-avid tumors. Recent progress in production of therapeutic copper-67 radionuclide invites clinical research in use of theranostic pair of CuCl and CuCl for cancer imaging and radionuclide therapy.

Citing Articles

Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.

Krecisz P, Stefanska K, Studzinski J, Pitucha M, Czylkowska A, Szymanski P J Med Chem. 2025; 68(3):2356-2376.

PMID: 39895089 PMC: 11831595. DOI: 10.1021/acs.jmedchem.4c02885.

Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.

Shabsigh M, Solomon L Chem Biomed Imaging. 2024; 2(9):615-630.

PMID: 39474267 PMC: 11503725. DOI: 10.1021/cbmi.4c00030.

Recent Advances in Preclinical Studies of the Theranostic Agent [Cu]CuCl.

Speltri G, Porto F, Boschi A, Uccelli L, Martini P Molecules. 2024; 29(17).

PMID: 39274933 PMC: 11397388. DOI: 10.3390/molecules29174085.

Current Role of PET CT in Staging and Management of Penile Cancers.

Mirvald C, Garaz R, Sinescu I, Preda A, Labanaris A, Yossepowitch O J Clin Med. 2024; 13(16).

PMID: 39201021 PMC: 11355205. DOI: 10.3390/jcm13164879.

Recent Progress in Synthesis of Tc-labeled Complexes with Nitroimidazoles as SPECT Probes for Targeting Tumor Hypoxia.

Nguyen A, Kim H Nucl Med Mol Imaging. 2024; 58(5):258-278.

PMID: 39036459 PMC: 11255181. DOI: 10.1007/s13139-024-00860-7.

References

Pinto C, Bucar S, Alves V, Fonseca A, Abrunhosa A, da Silva C . Copper-64 Chloride Exhibits Therapeutic Potential in Three-Dimensional Cellular Models of Prostate Cancer. Front Mol Biosci. 2020; 7:609172. PMC: 7736412. DOI: 10.3389/fmolb.2020.609172. View

Zhang H, Cai H, Lu X, Muzik O, Peng F . Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride. Acad Radiol. 2011; 18(12):1561-8. PMC: 3921175. DOI: 10.1016/j.acra.2011.08.006. View

Souliotis G, Rodrigues M, Wang K, Iacob V, Nica N, Roeder B . A novel approach to medical radioisotope production using inverse kinematics: A successful production test of the theranostic radionuclide Cu. Appl Radiat Isot. 2019; 149:89-95. DOI: 10.1016/j.apradiso.2019.04.019. View

Garcia-Perez F, Medina-Ornelas S, Barron-Barron F, Arrieta-Rodriguez O . Evaluation of non-small cell lung cancer by PET/CT with CuCl: initial experience in humans. Am J Nucl Med Mol Imaging. 2020; 10(3):143-150. PMC: 7364381. View

Guerreiro J, Alves V, Abrunhosa A, Paulo A, Gil O, Mendes F . Radiobiological Characterization of CuCl₂ as a Simple Tool for Prostate Cancer Theranostics. Molecules. 2018; 23(11). PMC: 6278521. DOI: 10.3390/molecules23112944. View

Wang Q, Song D, Ma X, Wu X, Jiang L . Preclinical PET imaging study of lung cancer with CuCl. Ann Nucl Med. 2020; 34(9):653-662. DOI: 10.1007/s12149-020-01491-6. View

Brady D, Crowe M, Turski M, Hobbs G, Yao X, Chaikuad A . Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014; 509(7501):492-6. PMC: 4138975. DOI: 10.1038/nature13180. View

Giesel F, Knorr K, Spohn F, Will L, Maurer T, Flechsig P . Detection Efficacy of F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2018; 60(3):362-368. PMC: 6424235. DOI: 10.2967/jnumed.118.212233. View

Safi R, Nelson E, Chitneni S, Franz K, George D, Zalutsky M . Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014; 74(20):5819-31. PMC: 4203427. DOI: 10.1158/0008-5472.CAN-13-3527. View

10.

Qin C, Liu H, Chen K, Hu X, Ma X, Lan X . Theranostics of malignant melanoma with 64CuCl2. J Nucl Med. 2014; 55(5):812-7. PMC: 4346241. DOI: 10.2967/jnumed.113.133850. View

11.

Cai H, Wu J, Muzik O, Hsieh J, Lee R, Peng F . Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med. 2014; 55(4):622-8. PMC: 4600613. DOI: 10.2967/jnumed.113.126979. View

12.

Righi S, Ugolini M, Bottoni G, Puntoni M, Iacozzi M, Paparo F . Biokinetic and dosimetric aspects of CuCl in human prostate cancer: possible theranostic implications. EJNMMI Res. 2018; 8(1):18. PMC: 5833894. DOI: 10.1186/s13550-018-0373-9. View

13.

Parmar A, Pascali G, Voli F, Lerra L, Yee E, Ahmed-Cox A . [Cu]CuCl PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis. Theranostics. 2018; 8(20):5645-5659. PMC: 6276294. DOI: 10.7150/thno.29840. View

14.

Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A . Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015; 29(6):482-8. DOI: 10.1007/s12149-015-0968-4. View

15.

Ferrari C, Niccoli Asabella A, Villano C, Giacobbi B, Coccetti D, Panichelli P . Copper-64 Dichloride as Theranostic Agent for Glioblastoma Multiforme: A Preclinical Study. Biomed Res Int. 2015; 2015:129764. PMC: 4663283. DOI: 10.1155/2015/129764. View

16.

Ceci F, Fendler W, Eiber M . A New Type of Prostate Cancer Imaging: Will CuCl PET/CT Flourish or Vanish?. J Nucl Med. 2017; 59(3):442-443. DOI: 10.2967/jnumed.117.199885. View

17.

Schuster D, Votaw J, Nieh P, Yu W, Nye J, Master V . Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48(1):56-63. View

18.

Kjaergaard K, Sandahl T, Frisch K, Vase K, Keiding S, Vilstrup H . Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [Cu]copper PET/CT. EJNMMI Radiopharm Chem. 2020; 5(1):15. PMC: 7303253. DOI: 10.1186/s41181-020-00100-1. View

19.

Mascia M, Villano C, De Francesco V, Schips L, Marchioni M, Cindolo L . Efficacy and Safety of the 64Cu(II)Cl2 PET/CT for Urological Malignancies: Phase IIa Clinical Study. Clin Nucl Med. 2021; 46(6):443-448. DOI: 10.1097/RLU.0000000000003658. View

20.

APELGOT S, Coppey J, Gaudemer A, Grisvard J, Guille E, Sasaki I . Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu. Int J Radiat Biol. 1989; 55(3):365-84. DOI: 10.1080/09553008914550421. View